Q Therapeutic System for Chronic Stroke Recovery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-26

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the effectiveness of the Q Therapeutic (BQ 3.0) System for individuals with chronic stroke in improving upper extremity function as determined by change in functional outcome measures after 3-month treatment, including in-clinic and at-home sessions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RESPARK - Brain Q for Chronic Stroke

NCT07095920

Stroke Chronic Stroke Patients Cerebrovascular Accident (CVA)

RECRUITING NA

Robots Paired With tDCS in Stroke Recovery

NCT01726673

Stroke

COMPLETED PHASE2

Brain Stimulation and Robotics in Chronic Stroke Motor Recovery

NCT03562663

Chronic Stroke

COMPLETED NA

Non-invasive Brain Stimulation and Occupational Therapy To Enhance Stroke Recovery

NCT00792428

Stroke Cerebrovascular Accident CVA +3 more

COMPLETED NA

Brain Stimulation and Tailored Interventions to Promote Recovery in Stroke Survivors

NCT02915185

Stroke

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the management of chronic stroke patients. Primarily, the trial will assess the System's impact on the upper extremity function through objective, validated clinical assessments. Secondary endpoints will evaluate additional functional and global disability, quality-of-life and safety outcomes.

The study intervention will consist of a total of 5 sessions per week over a period of 3 months (12 weeks) for a total of up to 60 sessions. Each participant must complete at least 40 sessions over the 12-week period to complete the protocol. No extra time will be given to complete all 60 sessions. Each session will last up to 60 minutes during which 40 minutes of active stimulation using the BQ 3.0 System will be administered to participants. The 40 minutes of stimulation will be paired with seated upper extremity (UE) exercises. Lastly, the device will be removed and 10 minutes of standing balance and LE strengthening exercises will be performed without stimulation. A battery of clinical assessments will be conducted before and after the 60 exercise sessions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Hemorrhage Brain Injury Cerebrovascular Accident (CVA) Chronic Stroke Patient

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the efficacy, and safety of the intervention in the management of chronic stroke patients.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BQ 3.0 Active Stimulation Group

60 sessions over a period of 12 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

Group Type EXPERIMENTAL

Q Therapeutic System (BQ 3.0) - Active

Intervention Type DEVICE

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Q Therapeutic System (BQ 3.0) - Active

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BQ 3.0 Active Stimulation Group Interventions

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* FMA-UE score between 22-50 (inclusive) of impaired limb.
* Difference between Screening and Baseline visit FMA-UE is 3 points or fewer.
* Age 18 to 80 years of age (inclusive).
* Stroke due to ischemia or to intracerebral hemorrhage.
* \>6 months to 5 years from index stroke onset.
* Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit.
* Able to sit with the investigational System for 40 consecutive minutes.
* Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me", or a non-verbal equivalent.
* Willingness to participate in physical exercises during study intervention sessions.
* Availability of a relative or other caregiver able to assist during study treatment sessions and visits.
* If female, not pregnant or breastfeeding or planning pregnancy during the study period.
* Informed consent signed by subject.

Exclusion Criteria

* Severe neglect impairment interfering with assessments or treatments.
* Severe depression, defined as GDS Score \>10/15
* The presence of MR-incompatible implanted devices or MR-incompatible retained objects; or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).
* Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
* Botulinum toxin to the paretic arm: received in the prior 3 months OR expected before the 6-Month Visit
* Severe UE spasticity, defined as presence of upper extremity contracture or modified Ashworth Scale score≥3 in either biceps or pectoralis
* Pre-existing neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
* Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
* Unstable serious illness/condition (eg, active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.
* Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
* Participation in another interventional trial that would conflict with the current study or clinical endpoint interference may occur.
* Participation in an upper extremity rehabilitation program provided by a licensed provider in the 4 weeks prior to the Screening visit, or a or planned participation in such program at any time between the Screening Visit and the primary endpoint visit.
* Employee of the Sponsor.
* Prisoner.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No